Advertisement

Pharmacy World and Science

, Volume 16, Issue 1, pp 22–26 | Cite as

Probenecid inhibits the glucuronidation of indomethacin andO-desmethylindomethacin in humans

A pilot experiment
  • T. B. Vree
  • M. van den Biggelaar-Martea
  • C. P. W. G. M. Verwey-van Wissen
  • E. W. J. van Ewijk-Beneken Kolmer
Practice/Case Reports

Abstract

Indomethacin is metabolized in humans byO-demethylation, and by acyl glucuronidation to the l-O-glucuronide. Indomethacin, its metabolite, and their conjugates can be measured directly by gradient high-pressure liquid chromatographic analysis without enzymic deglucuronidation. The pharrnacokinetic profile of indomethacin and some preliminary pharmacokinetic parameters of indomethacin obtained from one human volunteer are given. In plasma only the parent drug indomethacin is present, while in urine the acyl and ether glucuronides are present in high concentrations. This confirms other reports that indomethacin andO-desmethylindomethacin may be glucuronidated in the kidney. Probenecid is a known substrate for renal glucuronidation. If indomethacin is glucuronidated in the human kidney like probenecid, then this glucuronidation might be reduced or inhibited under probenecid co-medication. This pilot experiment shows that probenecid reduced the acyl glucuronidation of indomethacin by 50% and completely inhibited the formation ofO-desmethylindomethacin acyl and ether glucuronide.

Keywords

Drug interactions Glucuronates Indomethacin Metabolites Pharmacokinetics Probenecid 

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. 1.
    Harman RE, Meisinger MAP, Davis GE, Kuehl FA. The metabolites of indomethacin, a new anti-inflammatory drug. J Pharmacol Exp Ther 1964;143:215.Google Scholar
  2. 2.
    Helleberg L. Clinical pharmacokinetics of indomethacin. Clin Pharmacokinet 1981;6:245–58.Google Scholar
  3. 3.
    Hucker HB, Zacchel AG, Cox SV, Brodie DA, Cantwell NHR. Studies on the absorption, distribution and excretion of indomethacin in various species. J Pharmacol Exp Ther 1966;153:237–49.Google Scholar
  4. 4.
    Duggan DE, Hogans AF, Kwan KC, McMahon FG. The metabolism of indomethacin in man. J Pharmacol Exp Ther 1972;181:563–75.Google Scholar
  5. 5.
    Faed M. Properties of acyl glucuronides; implications for studies of the pharmacokinetics and metabolism of acidic drugs. Drug Metab Rev 1984;15:1213–49.Google Scholar
  6. 6.
    Vree TB, van den Biggelaar-Martea M, Verwey-van Wissen CPWGM. Determination of indomethacin, its metabolites with their acyl glucuronides in human plasma and urine by means of direct gradient HPLC analysis. J Chromatogr Biomed Appl 1993;616:271–82.Google Scholar
  7. 7.
    Vree TB, van den Biggelaar-Martea M, Beneken Kolmer EWJ, Hekster YA. Direct gradient reversed phase HPLC analysis of nalidixic acid, 7-hydroxymethylnalidixic acid, 7-carboxy-nalidixic acid, and their corresponding glucuronide conjugates in man. Pharm World Sci 1993; 15:98–104.Google Scholar
  8. 8.
    Vree TB, Beneken Kolmer EWJ. Direct measurement of probenecid and its glucuronide conjugate by means of HPLC in plasma and urine of humans. Pharm Weekbl Sci 1992; 14:83–7.Google Scholar
  9. 9.
    Vree TB, van Ewijk-Beneken Kolmer EWJ, Wuis EW, Hekster YA. Capacity-limited renal glucuronidation of probenecid by humans. A pilotV max-finding study. Pharm Weekbl Sci 1992;14:325–31.Google Scholar
  10. 10.
    Vree TB, van den Biggelaar-Martea M, van Ewijk-Beneken Kolmer EWJ, Hekster YA. Probenecid inhibits the renal clearance and renal glucuronidation of nalidixic acid. A pilot experiment. Pharm World Sci 1993;15:165–70.Google Scholar
  11. 11.
    Proost JH, Meijer DKW. MW/Pharm, an integrated software package for drug dosage regimen calculation and therapeutic drug monitoring. Comput Biol Med 1992;22:155–63.Google Scholar
  12. 12.
    Moolenaar F, Crancrinus S, Visser J, De Zeeuw D, Meijer DKF. Clearance of indomethacin occurs predominantly by renal glucuronidation. Pharm Weekbl Sci 1992;14:191–5.Google Scholar
  13. 13.
    Vree TB, Hekster YA, Anderson PG. Contribution of the human kidney to the metabolic clearance of drugs. Ann Pharmacother 1992;26:1421–8.Google Scholar
  14. 14.
    Vree TB, van den Biggelaar-Martea M, Verwey-van Wissen CPWGM. Determination of naproxen and its metaboliteO-desmethylnaproxen with their acyl glucuronides in human plasma and urine by means of direct gradient HPLC. J Chromatogr Biomed Appl 1992;578:239–49.Google Scholar
  15. 15.
    Vree TB, van den Biggelaar-Martea M, Verwey-van Wissen CPWGM, Vree JB, Guelen PJM. Pharmacokinetics of naproxen, its metaboliteO-desmethylnaproxen and their acyl glucuronides in humans. The possible involvement of the enterohepatic loop. Biopharm Drug Dispos 1993;14:491–502.Google Scholar
  16. 16.
    Vree TB, van den Biggelaar-Martea M, Verwey-van Wissen CPWGM, Vree ML, Guelen PJM. The pharmacokinetics of naproxen, its metaboliteO-desmethylnaproxen and their acyl glucuronides in humans. Effect of cimetidine. Br J Clin Pharmacol 1993;35:467–72.Google Scholar
  17. 17.
    Cox PGF, Moons MM, Russel FGM, van Ginneken CAM. Naproxen and indomethacin: disposition and effects in the isolated perfused rat kidney. Toxicol Lett 1990;53:175–7.Google Scholar
  18. 18.
    Upton RA, Buskin JN, Williams RL, Holford NHG, Riegelman S. Negligible excretion of unchanged ketoprofen, naproxen and probenecid in urine. J Pharm Sci 1980;69:1254–7.Google Scholar
  19. 19.
    Skeith MD, Simkin PA, Healy LA. The renal excretion of indomethacin and its inhibition by probenecid. Clin Pharmacol Ther 1968;9:89–93.Google Scholar
  20. 20.
    Vree TB, van Ewijk-Beneken Kolmer EWJ, Nouws JFM. Direct gradient HPLC analysis and preliminary pharmacokinetics of flumequine and flumequine acyl glucuronide in humans. J Chromatogr Biomed Appl 1992;579:131–41.Google Scholar

Copyright information

© Royal Dutch Association for Advancement of Pharmacy 1994

Authors and Affiliations

  • T. B. Vree
    • 1
  • M. van den Biggelaar-Martea
    • 2
  • C. P. W. G. M. Verwey-van Wissen
    • 2
  • E. W. J. van Ewijk-Beneken Kolmer
    • 2
  1. 1.Department of Clinical Pharmacy, Institute of AnaesthesiologyAcademic Hospital Sint RadboudGA NijmegenThe Netherlands
  2. 2.Department of Clinical PharmacyAcademic Hospital Sint RadboudThe Netherland

Personalised recommendations